Search is Powered by Google
Cancer / Oncology News

Institute Of Cancer Research Named UK's Top Research Centre

Main Category: Cancer / Oncology
Article Date: 23 Dec 2008 - 1:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

The Institute of Cancer Research has been ranked as the UK's leading academic research centre by the Times Higher Education, today.

The coveted independent ranking of the UK's 132 educational research centres was based on the Higher Education Funding Council's Research Assessment Exercise.

Educational organisations' research was given a 1 to 4 star rating, with The Institute receiving the highest percentage of research assessed as four stars, world leading in the areas of biological sciences and cancer studies.

Professor Peter Rigby, Chief Executive of The Institute of Cancer Research says.

"I am delighted by this external validation of the extremely high quality of our research. This is a great tribute to all of my colleagues who work so hard on behalf of cancer patients."

The review comes as The Institute is about to mark its centenary in 2009.

The Institute is at the forefront of the world's leading cancer research developments. It is a world leader in both genetics and drug research.

Major achievements that have taken place at The Institute since the previous RAE results in 2001:

-- The BRAF gene involved in 70 per cent of melanomas has been identified, the development of drugs to target the disease is underway

-- Demonstrated a new class of drugs called PARP inhibitors specifically target tumours carrying the BRCA1 and 2 mutations

-- Identification of four new breast cancer genes

-- Genetic susceptibility to lung cancer, prostate and chronic lymphocytic leukaemia revealed

-- The structure of the HSP90 protein involved in the development of cancer revealed leading to the development of a new class of drugs to provide a potential treatment for prostate, breast, bowel, ovarian and kidney cancer

-- Successful clinical trials of the drug abiraterone to treat prostate cancer

-- Stem cells that cause childhood leukaemia identified

The Institute of Cancer Research

The Institute of Cancer Research is Europe's leading cancer research centre with expert scientists working on cutting edge research. In 2009, The Institute marks its 100 years of world leading research into cancer prevention, diagnosis and treatment. The Institute is a charity that relies on voluntary income. It is one of the world's most cost-effective major cancer research organisations with over 95p in every £ directly supporting research. For more information please visit http://www.icr.ac.uk.

Source
Cathy Beveridge
Institute of Cancer Research




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...